Rosetta Genomics (NASDAQ: ROSG) is an international company leveraging a growing IP portfolio to develop and commercialize microRNA-based and other molecular diagnostic programs in cancer and various other indications. In 2016, Rosetta was primarily focused on the commercial launch of its Reveal assay for the classification of indeterminate thyroid nodules, and it signed an exclusive distribution agreement with Rhenium Ltd. for the sales and marketing of Reveal in Israel. In a December earnings release, Rosetta Genomics said it expects FY2017 RosettaGX Reveal revenue to be between $4 million and $5 million. The company is also advancing a number of other corporate initiatives, and, in November 2016, entered into a research agreement with Sheba Medical Center at Tel HaShomer, Israel, to develop a microRNA-based signature to predict survival benefit of Nivolumab, an immunotherapy drug marketed as Opdivo® for the treatment of lung cancer. Pivoting from these advances, Rosetta CEO Kenneth Berlin said the company is poised to achieve “a series of value-creating milestones” in 2017.
To learn more visit: www.rosettagx.com
About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company now offers core FISH, IHC and PCR-based testing capabilities and partnerships in Pathology, Oncology and Urology that provide additional content and platforms that complement Rosetta’s microRNA and Next-Gen Sequencing offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of indeterminate thyroid FNA smears, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer